Rovunaptabin
Based on 1 Customer Validation
Rovunaptabin (ARC 183) is an aptamer, a single-stranded DNA molecule composed of 15 deoxynucleotides. It acts as a broad-spectrum neutralizer of pathogenic G-protein-coupled receptor autoantibodies. Rovunaptabin can be used in research related to cardiomyopathy and pulmonary hypertension.
For research use only. We do not sell to patients.
- Purity: 99.49%
- CAS No.: 145563-68-4
- Molecular Weight:4726.07
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Rovunaptabin (100 nM; 1 h) shows species-specific neutralization in spontaneously beating neonatal rat cardiomyocytes, fully neutralizing rat and rabbit G-protein-coupled receptor autoantibodies, partially neutralizing goat autoantibodies, and failing to neutralize chicken autoantibodies[1].
Rovunaptabin (100 nM) binds to the Fab region of human ETA-receptor and beta1-adrenoceptor autoantibodies, preventing restoration of agonistic activity via cross-linking in spontaneously beating neonatal rat cardiomyocytes[1].
Rovunaptabin (1 μM) forms a detectable complex with 1.5 μM human beta1-adrenoceptor autoantibodies in an electrophoretic mobility shift assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Treatment with Rovunaptabin (BC 007) (1-4 mg/kg; i.v. infusion over 20 min; single dose; second single dose (9 months after initial)) safely neutralizes β1-adrenergic receptor autoantibodies in β1-AAB-positive Doberman Pinschers with dilated cardiomyopathy, reduces or stabilizes left ventricular volumes during β1-AAB-free periods, and significantly prolongs median cardiac survival to 572 days[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:purebred Doberman Pinschers[2]
-
Dosage:1-4 mg/kg; 1 mg/kg
-
Administration:i.v. infusion over 20 min; single dose;
-
Result:Neutralized β1-adrenergic receptor autoantibodies in β1-AAB-positive Doberman Pinschers with dilated cardiomyopathy. Reduced or stabilized left ventricular volumes during β1-AAB-free periods, and significantly prolonged median cardiac survival to 572 days.
Chemical Information
-
CAS No. 145563-68-4
-
Appearance Solid
-
Molecular Weight 4726.07
-
Color White to off-white
-
SMILES
DNA, d(G-G-T-T-G-G-T-G-T-G-G-T-T-G-G)
-
Synonyms
ARC 183; BC 007
-
Sequence
DNA, d(G-G-T-T-G-G-T-G-T-G-G-T-T-G-G)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (1518 KB)
References
[1]. Haberland A, et al. Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors. Eur J Pharmacol. 2016;789:37-45. [Content Brief]
[2]. Werner S, et al. The aptamer BC 007 for treatment of dilated cardiomyopathy: evaluation in Doberman Pinschers of efficacy and outcomes. ESC Heart Fail. 2020;7(3):844-855. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- Rovunaptabin
- 145563-68-4
- ARC 183
- BC 007
- ARC183
- ARC-183
- BC007
- BC 007
- BC-007
- G Protein-coupled Receptor Kinase (GRK)
- ET?-receptor
- neonatal rat cardiomyocytes
- Doberman Pinschers
- M2-muscarinic receptor
- β1-adrenoceptor
- α1-adrenoceptor
- β2-adrenoceptor
- G-protein-coupled receptor autoantibodies
- AT1-receptor
- proteinase activated receptor
- Inhibitor
- inhibitor
- inhibit